We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

maandag 4 september 2017

Nature Reviews Urology - Table of Contents alert Volume 14 Issue 9

If you are unable to see the message below, click here to view.
Nature Reviews Urology
 
 
TABLE OF CONTENTS
 
September 2017 Volume 14 Number 9
Nature Reviews Urology cover
2016 2-year Impact Factor 7.735
Journal Metrics 2-year Median 5
In this issue
Comment
Research Highlights
News and Views
Correspondence
Reviews
Perspective
 
Also this month
 Featured article:
Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy
Jeffrey J. Tosoian, Ridwan Alam, Mark W. Ball, H. Ballentine Carter and Jonathan I. Epstein

 

 
Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
   
Comment: Variation in clinical practice: forests and trees revisited
Christopher J. D. Wallis, C. David Naylor & Allan S. Detsky

Published online: 27 June 2017
p511 | doi:10.1038/nrurol.2017.102

Abstract | Full Text | PDF | Supplementary information

 
Comment: Bladder cancer: oligometastases and imaging
Laura S. Mertens & Simon Horenblas

Published online: 20 June 2017
p513 | doi:10.1038/nrurol.2017.96

Abstract | Full Text | PDF

 
RESEARCH HIGHLIGHTS
 
Top

Bladder cancer: PPARγ-RXRα alterations promote immune evasion
Published online: 08 August 2017
p515 | doi:10.1038/nrurol.2017.133

PDF


Prostate cancer: The pathway to progression: DHT biosynthesis
Published online: 16 August 2017
p516 | doi:10.1038/nrurol.2017.118

PDF


Infection: Proceed with CAUTIon
Published online: 04 July 2017
p517 | doi:10.1038/nrurol.2017.105

PDF


Incontinence: Patients prefer combination therapy
Published online: 01 August 2017
p517 | doi:10.1038/nrurol.2017.129

PDF


Kidney cancer: Savolitinib — a saviour for papillary RCC?
Published online: 11 July 2017
p518 | doi:10.1038/nrurol.2017.114

PDF


Immunology: PD-1 and PD-L1 prognostic in UTUC
Published online: 18 July 2017
p518 | doi:10.1038/nrurol.2017.120

PDF


Prostate cancer: Mutations in ctDNA reflect features of metastatic disease
Published online: 18 July 2017
p518 | doi:10.1038/nrurol.2017.121

PDF


Infection: The urinary microbiota is unique and resilient
Published online: 11 July 2017
p519 | doi:10.1038/nrurol.2017.116

PDF


Prostate cancer: Subtype linked to germline variant
Published online: 25 July 2017
p519 | doi:10.1038/nrurol.2017.122

PDF


 


IN BRIEF

Urothelial carcinoma: Genomic characterization of UTUC | Sexual dysfunction: Shortened CCH treatment for Peyronie's disease | Urinary incontinence: Evaluating bladder wall properties with vibrometry | Urinary incontinence: Stem cell therapy for chronic bladder ischaemia
PDF

Nature Reviews Urology
JOBS of the week
Tenure-track Assistant or Associate Professor in Physiology
University of Illinois
More Science jobs from
Nature Reviews Urology
EVENT
Tumor Models Summit
09.11.18
Prague, Czech Republic
More science events from
 
NEWS AND VIEWS
 
Top
Prostate cancer: Microbiome — the 'unforeseen organ'
Muhammed A.P. Manzoor & Punchapaddy-Devasya Rekha

Published online: 27 June 2017
p521 | doi:10.1038/nrurol.2017.97

The advent of molecular methods for the identification and characterization of the microbiome has led researchers to understand the role of the microbiota in various clinical conditions. Research by Cavarretta and colleagues has revealed the presence of microbial dysbiosis and its potential relationship with pathophysiology in the prostate tumour microenvironment. This finding could potentially enable future investigations that clarify the role of the microbiota in the development of prostate cancer and its future management, from a different perspective.
Full Text | PDF

 
 
CORRESPONDENCE
 
Top
Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?
Syed Imran A. Shah, Hannah C. P. Wilson & Paul D. Abel

Published online: 08 August 2017
p575 | doi:10.1038/nrurol.2017.126

Full Text | PDF
 
 
REPLY
 
Top
Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?
Antonello Veccia, Francesca Maines & Orazio Caffo

Published online: 08 August 2017
p575 | doi:10.1038/nrurol.2017.127

Full Text | PDF
 
 
 
REVIEWS
 
Top
Varicocele and male infertility
Christian Fuglesang S. Jensen et al.

Published online: 04 July 2017
p523 | doi:10.1038/nrurol.2017.98

Varicocele is the most common correctable cause of male infertility, but some men with varicoceles are able to father children, even without intervention, and so the link between varicoceles and male infertility remains a matter of debate. Oxidative stress seems to be a central mechanism of testicular damage; however, no single theory to explain the differential effect of varicoceles on infertility has been suggested. In this Review, a panel of expert authors discuss the epidemiology and pathophysiology of varicocele-related infertility, and consider the optimal treatment for men with varicocele.
Abstract | Full Text | PDF

 
Risk factors for cryptorchidism
Jason K. Gurney et al.

Published online: 27 June 2017
p534 | doi:10.1038/nrurol.2017.90

Undescended testis — known as cryptorchidism — is one of the most common congenital abnormalities observed in boys, and is one of the few known risk factors for testicular cancer. The key factors that contribute to the occurrence of cryptorchidism remain elusive and a broad range of putative risk factors have been evaluated, but their plausibility is still in question.
Abstract | Full Text | PDF

 
Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach
Shankar Siva et al.

Published online: 20 June 2017
p549 | doi:10.1038/nrurol.2017.87

Renal cell carcinoma (RCC) is largely percieved to be radioresistant, owing to the failure of several clinical trials involving fractionated radiotherapy. However, following the availability of new technologies, which enable the delivery of ablative doses of radiation, in fewer fractions, excellent responses have been observed among patients with RCC. In this Review, the authors describe the evidence supporting the use of ablative-dose radiotherapy, either alone, or in combination with other therapies in patients with RCC.
Abstract | Full Text | PDF

 
 
 
PERSPECTIVE
 
Top
TIMELINE
Landmarks in the treatment of muscle-invasive bladder cancer
Niyati Lobo et al.

Published online: 04 July 2017
p565 | doi:10.1038/nrurol.2017.82

Muscle-invasive bladder cancer (MIBC) is an aggressive disease associated with high morbidity and mortality. In this Perspective, the authors describe the timeline of advances in treating MIBC, including radical cystectomy with pelvic lymph node dissection, the creation of increasingly sophisticated urinary diversions, use of cisplatin-based neoadjuvant chemotherapy, bladder-sparing protocols, and immunotherapy.
Abstract | Full Text | PDF

 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Urology was previously published as Nature Clinical Practice Urology.
 

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature